All articles tagged with #foundayo
Eli Lilly CEO Dave Ricks says about 700,000 new seniors started GLP-1 treatments since Medicare’s obesity-drug coverage began in July, with roughly 70% on Lilly medicines; Zepbound is the biggest early beneficiary, while Lilly’s oral Foundayo is gaining traction for a convenient option, and the rollout—via the Bridge program with a $50 co-pay—has been smooth and encouraging for expanding access.
Eli Lilly is breaking ground on a $6.5 billion Houston manufacturing complex to ramp up production of Foundayo, its GLP-1 obesity pill, with operations expected by 2030; the facility will also manufacture active ingredients for other Lilly medicines as the company expands its share in the oral GLP-1 market and pursues broader international launches amid competition from Novo Nordisk.
Britain’s MHRA approved Eli Lilly’s Foundayo (orforglipron) for weight management and type 2 diabetes, marking Lilly’s first European license for the oral GLP-1 drug. The EU decision is not expected until next year. An NHS coverage decision will be made by NICE on November 18, with initial access likely in the private market; Novo Nordisk’s Wegovy pill is expected to reach EU markets soon, increasing competition. The UK remains the only country with a bilateral deal with the US to pay more for medicines.
Eli Lilly beat Q2 estimates as demand for obesity and diabetes drugs fueled stronger earnings, prompting a raise in 2026 revenue guidance to $85–$87 billion. Q2 revenue was $22.97 billion with adjusted EPS of $8.38; Mounjaro worldwide sales reached $9.94 billion, Zepbound US sales were $4.93 billion, and Foundayo contributed $98 million in its first quarter of selling. International sales surged while price cuts trimmed some gains. The company highlighted ongoing aggressive M&A activity and expected benefits from Medicare coverage for obesity drugs.
Novo Nordisk and Eli Lilly highlighted the rapid uptake of their GLP-1 obesity pills at a major meeting and outlined plans tied to Medicare’s July rollout, which will cover weight‑loss GLP-1 drugs for about $50 a month. Wegovy prescriptions topped 3 million within roughly five months, while Foundayo is gaining momentum, underscoring a race between the rivals on convenience versus potency and health benefits. Both firms are pushing for broader insurance coverage, studying cost impacts, and advancing pipelines (Lilly’s retatrutide and Novo’s CagriSema) to strengthen their positions beyond current drugs.
CVS Caremark will restore Eli Lilly’s obesity drug Zepbound to its commercial formularies on October 1 and add Lilly’s obesity pill Foundayo as a co‑preferred option, aiming to provide equal access and copays with Novo Nordisk’s Wegovy (as low as $25 a month for eligible commercially insured patients). All three of the nation’s largest pharmacy benefit managers now cover Lilly’s obesity portfolio, a move that could boost Foundayo sales in the second half of the year as employers and health plans seek more affordable GLP‑1 weight‑loss options.
CVS Caremark will restore coverage for Eli Lilly’s Zepbound on Oct. 1 and start covering Lilly’s obesity pill Foundayo on June 1 on its standard drug plans, putting Lilly and Novo Nordisk on equal footing in major plans and expanding access for patients. The change follows CVS’s previous deal that favored Novo Nordisk’s Wegovy, and Caremark’s formulary will offer co‑preferred GLP-1 options for weight loss, though sponsors can opt out, meaning coverage isn’t guaranteed for all. CVS expects the shifts to drive 10%–15% savings in the weight‑management category as Lilly and Novo Nordisk negotiate pricing.”,
Novo Nordisk’s Wegovy oral pill has gained strong early momentum since its January launch, aided by aggressive marketing and a lower monthly price, while Lilly’s Foundayo is ramping up more slowly. Telehealth platforms report rapid uptake for Wegovy, and investors are watching first-quarter results and potential international expansion as the GLP-1 pill market expands beyond injections.
Eli Lilly more than doubled its Q1 profits as demand for obesity and diabetes medications drove revenue higher, with Mounjaro sales at $8.7bn and Zepbound at $4.2bn (up 80%), prompting a raised outlook. Foundayo was approved and launched this month but isn’t included in the quarter’s figures. Shares rose about 9%, and Lilly faces competitive pressure from Novo Nordisk while Medicare deals helped push Zepbound prices down even as volumes grew; investors will watch for weekly prescription data and updates on Foundayo’s performance.
Eli Lilly beat Q1 estimates with about $19.8B in revenue and $8.55 in adjusted EPS, powered by 125% growth in Mounjaro to $8.66B worldwide and $4.2B in U.S. sales, and $4.16B in U.S. Zepbound sales. The results prompted a $2B raise to full-year revenue guidance to $82–85B and higher adjusted EPS of $35.50–$37. Foundayo, the obesity GLP-1 pill, launched in Q2 and isn’t included in this report. Lilly maintains roughly 60% of the U.S. GLP-1 market, but faces pricing pressure and upcoming Medicare coverage changes as global GLP-1 use could reach about 30M by end-2026.
Premarket, Eli Lilly shares fell after IQVIA data cited by Bloomberg showed Lilly’s obesity drugs Foundayo (oral) and Zepbound trailed Novo Nordisk’s Wegovy in weekly prescriptions; Zepbound fell about 2% week over week while Wegovy rose about 7% in the same period, and Foundayo posted 3,707 prescriptions in its first full week versus Wegovy’s roughly 18,410 in its first full week; analysts caution that one week of data isn’t definitive, but weak early momentum could pressure Lilly stock if the trend persists.
BMO Capital Markets reiterates a Buy-equivalent rating on Eli Lilly (LLY) with a $1,300 target as the obesity pill Foundayo rolls out. Lilly expects $1.5–$2.8 billion in U.S. sales this year and up to $36 billion in peak annual sales globally, with Foundayo distributed through Weight Watchers (WW) and Amazon among other channels. The FDA approved Foundayo on April 1, and Wall Street remains bullish, with a consensus Strong Buy from 19 analysts and an average target around $1,247, implying roughly 31% upside from current levels.
In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.
Amazon Pharmacy will offer Eli Lilly’s new oral GLP-1 drug Foundayo with real-time availability and transparent pricing (insurance as low as $1/day or $25/mo; cash $5/day or $149/mo; automatic coupons), plus Same-Day Delivery nationwide and pharmacist-supported in-office kiosks at select One Medical locations, expanding access from about 3,000 to 4,500 cities by year-end; remote areas will have next-day to three-day delivery.